Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
I'm LongbridgeAI, I can summarize articles.
Affinia Therapeutics has received approval from Health Canada to initiate the UPBEAT© trial, a Phase 1/2 clinical trial for AFTX-201, aimed at treating BAG3-associated dilated cardiomyopathy (DCM). AFTX-201 is designed to address the genetic cause of BAG3 DCM with a one-time intravenous administration. The trial will evaluate the safety and efficacy of AFTX-201, following its acceptance by the FDA and receiving Fast Track designation. The UPBEAT trial will include multiple sites in the U.S. and Canada, focusing on patients with genetically confirmed BAG3 DCM.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments